Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Zevra Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $83.87M. For fiscal 2025 it was -$58.89M. The highest annual figure on record is $7.99M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.89M | – |
| FY2024 | Dec 31, 2024 | -$80.61M | – |
| FY2023 | Dec 31, 2023 | -$48.60M | – |
| FY2022 | Dec 31, 2022 | -$41.62M | -621.2% |
| FY2021 | Dec 31, 2021 | $7.99M | – |
| FY2020 | Dec 31, 2020 | -$5.34M | – |
| FY2019 | Dec 31, 2019 | -$20.03M | – |
| FY2018 | Dec 31, 2018 | -$55.58M | – |
| FY2017 | Dec 31, 2017 | -$33.03M | – |
| FY2016 | Dec 31, 2016 | -$37.31M | – |
| FY2015 | Dec 31, 2015 | -$22.73M | – |
| FY2014 | Dec 31, 2014 | -$16.37M | – |
| FY2013 | Dec 31, 2013 | -$4.65M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.14M | – |
| Q1 FY2026 | Mar 31, 2026 | $52.51M | – |
| Q4 FY2025 | Dec 31, 2025 | $9.68M | – |
| Q3 FY2025 | Sep 30, 2025 | $4.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$69.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.37M | – |
| Q3 FY2023 | Sep 30, 2023 | -$15.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.01M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.23M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.59M | -516.9% |
| Q1 FY2022 | Mar 31, 2022 | -$1.79M | -125.5% |
| Q4 FY2021 | Dec 31, 2021 | -$2.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.16M | – |
| Q2 FY2021 | Jun 30, 2021 | $5.90M | +121.6% |
| Q1 FY2021 | Mar 31, 2021 | $7.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.15M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.15M | -134.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.34M | – |
| Q3 FY2019 | Sep 30, 2019 | $3.31M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.72M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.88M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.83M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.69M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.07M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.53M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.14M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.76M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.36M | – |
See a number that looks wrong?